Skip to content

Effect of Breastfeeding Optimization on Early Vascular Development

BReast Feeding Attitude and Volume Optimization (BRAVO) Trial: A Randomized Breast Feeding Optimization Experiment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01566812
Acronym
BRAVO
Enrollment
1000
Registered
2012-03-29
Start date
2012-06-30
Completion date
2018-02-28
Last updated
2017-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding, Cardiovascular Diseases

Keywords

Breast Feeding, Cardiovascular Risk

Brief summary

This study aims to find out whether breast feeding optimization will increase breast feeding rates and to evaluate its effect on cardiovascular risk and general health of children.

Detailed description

Breast feeding is suggested to give many benefits for babies and there are some initial prove that it might affect their future health, including the development of cardiovascular diseases. In Indonesia, breast feeding rates are very low, while there is a strong upsurge of cardiovascular disease. In this study, we propose to randomly allocate pregnant Indonesian women who plan to give breast feeding for no more than two months, to either care as usual or to a breast feeding empowerment program lasting to 6 months post partum. At the age of one year, all randomized offspring will undergo non-invasive echographic aortic vascular measurements and cardiovascular risk profiling. Measurements for assessing children's general health status will also be performed, including growth monitoring, repeated lung function test, and microbiomic sampling.

Interventions

BEHAVIORALBreast feeding optimization

Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support

BEHAVIORALUsual care

Usual care applied in the hospital

Sponsors

CEEBM
CollaboratorUNKNOWN
Julius Center
CollaboratorOTHER
Budi Kemuliaan Hospital
CollaboratorUNKNOWN
Indonesia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Plan to breast feed for ≤2 months * Residing in vicinity ≤ 5 km from the hospital/agree to comply to health visit schedule * Telephone communication is possible * No known HIV or active tuberculosis in mother * Uncomplicated pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Cardiovascular risk5 yearsAbdominal aortic/carotid intima media thickness, distensibility, elastic modulus; pulse wave velocity, stiffness index, blood pressure; echocardiography: ejection fraction (%), fractional shortening (%), TAPSE (cm), cardiac index (L/min/m2), LV mass (grams)
Breastfeeding habits1 yearsBreastfeeding practice: Y/N, night/day, frequency (time interval between breastfeeding, e.g 2 hours) Supplementary formula: frequency/day, volume per feeding Complementary feeding: Y/N, type of foods; frequency/day Employer and employee satisfaction

Secondary

MeasureTime frameDescription
Microbiome1 yearsInfant nasopharyngeal & oral flora, digestive tract/feces flora, maternal oropharyngeal evaluated using PCR and culture.
Development5 yearsBayley Infant Scales, IQ
Child growth5 yearsBody weight, height, head circumference, abdominal circumference
Inflammation1 yearSerum hs-CRP, Fibrinogen
Illness1 yearInfection/fever, allergic symptoms, wheezing, upper/lower respiratory disease, gastrointestinal symptoms
Lung function5 yearsResistance, compliance, time constant, FVC (liters), FEV1 (liters) measured by spirometry

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026